Chronic Pain – Current Treatment – Detailed, Expanded Analysis (US)
The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the absence of targeted mechanism-based therapies. As a result, it is difficult to provide adequate analgesia to all patients despite the extensive armamentarium of chronic pain therapies, including the increasing availability of cost-effective generic treatments. Indeed, the chronic pain therapy market is characterized by the high cost of pain management stemming from the long duration of treatment and from the many lines of therapy often required to maintain analgesic effects and by the increasing prevalence of key population segments, including osteoarthritis pain and chronic back pain. In recent years, the field has seen the emergence of abuse-deterrent formulations of opioid analgesics, which offer incremental advantages in safety and tolerability but struggle to compete against long-generic and firmly entrenched opioid analgesics as well as brand and generic nonopioid therapies.
Questions answered:
- How is chronic pain being treated in the United States today, and what are the drivers and constraints influencing physicians’ treatment decisions?
- What impact have the more-recent launches of new brands such as Collegium Pharmaceutical’s Xtampza ER (oxycodone ER) and Iroko Pharmaceuticals’ Vivlodex (low-dose meloxicam) had on physician prescribing behavior for chronic pain?
- What factors drive switching between or discontinuation of select analgesics?
- How does the availability of abuse-deterrent opioid analgesic reformulations and branded nonopioid therapies impact physician prescribing of generic agents within the respective drug classes?
Product description:
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Table of contents
- Chronic Pain - Current Treatment - Detailed, Expanded Analysis (US)
- Current Treatment: Physician Insights Chronic Pain US July 2019
- Current Treatment: Physician Insights Chronic Pain US July 2019 Survey
Joyce Spadafora, A.L.M., is a senior analyst on the CNS/Ophthalmology Disorders team. She authors content on various chronic pain, psychiatric, and neurological indications. Prior to joining the company, she spent several years in the biotech industry focusing on new product development and consulting. She holds a master’s degree in extension studies in psychology from Harvard University and a bachelor’s of science in mechanical engineering with biology from the Massachusetts Institute of Technology.